595 related articles for article (PubMed ID: 23545439)
1. Optic neuritis in neuromyelitis optica.
Levin MH; Bennett JL; Verkman AS
Prog Retin Eye Res; 2013 Sep; 36():159-71. PubMed ID: 23545439
[TBL] [Abstract][Full Text] [Related]
2. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link.
Jarius S; Wildemann B
Med Hypotheses; 2013 Dec; 81(6):1090-5. PubMed ID: 24182872
[TBL] [Abstract][Full Text] [Related]
3. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.
Verkman AS; Phuan PW; Asavapanumas N; Tradtrantip L
Brain Pathol; 2013 Nov; 23(6):684-95. PubMed ID: 24118484
[TBL] [Abstract][Full Text] [Related]
4. Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G.
Asavapanumas N; Ratelade J; Papadopoulos MC; Bennett JL; Levin MH; Verkman AS
J Neuroinflammation; 2014 Jan; 11():16. PubMed ID: 24468108
[TBL] [Abstract][Full Text] [Related]
5. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
Marignier R; Ruiz A; Cavagna S; Nicole A; Watrin C; Touret M; Parrot S; Malleret G; Peyron C; Benetollo C; Auvergnon N; Vukusic S; Giraudon P
J Neuroinflammation; 2016 May; 13(1):111. PubMed ID: 27193196
[TBL] [Abstract][Full Text] [Related]
6. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
Wu Y; Zhong L; Geng J
Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
[TBL] [Abstract][Full Text] [Related]
7. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.
Lucchinetti CF; Guo Y; Popescu BF; Fujihara K; Itoyama Y; Misu T
Brain Pathol; 2014 Jan; 24(1):83-97. PubMed ID: 24345222
[TBL] [Abstract][Full Text] [Related]
8. Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice.
Xiang W; Xie C; Luo J; Zhang W; Zhao X; Yang H; Cai Y; Ding J; Wang Y; Hao Y; Zhang Y; Guan Y
Front Immunol; 2021; 12():727750. PubMed ID: 34721390
[TBL] [Abstract][Full Text] [Related]
9. [NMO spectrum disorders and anti AQP4 antibody].
Takai Y; Misu T; Takahashi T; Nakashima I; Fujihara K
Brain Nerve; 2013 Apr; 65(4):333-43. PubMed ID: 23568981
[TBL] [Abstract][Full Text] [Related]
10. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies.
Nicchia GP; Mastrototaro M; Rossi A; Pisani F; Tortorella C; Ruggieri M; Lia A; Trojano M; Frigeri A; Svelto M
Glia; 2009 Oct; 57(13):1363-73. PubMed ID: 19229993
[TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies.
Ratelade J; Verkman AS
Int J Biochem Cell Biol; 2012 Sep; 44(9):1519-30. PubMed ID: 22713791
[TBL] [Abstract][Full Text] [Related]
12. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays.
Phuan PW; Ratelade J; Rossi A; Tradtrantip L; Verkman AS
J Biol Chem; 2012 Apr; 287(17):13829-39. PubMed ID: 22393049
[TBL] [Abstract][Full Text] [Related]
13. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.
Ratelade J; Smith AJ; Verkman AS
Exp Neurol; 2014 May; 255():145-53. PubMed ID: 24636863
[TBL] [Abstract][Full Text] [Related]
14. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report.
Misu T; Fujihara K; Nakamura M; Murakami K; Endo M; Konno H; Itoyama Y
Tohoku J Exp Med; 2006 Jul; 209(3):269-75. PubMed ID: 16778375
[TBL] [Abstract][Full Text] [Related]
15. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.
Ratelade J; Asavapanumas N; Ritchie AM; Wemlinger S; Bennett JL; Verkman AS
Acta Neuropathol; 2013 Nov; 126(5):699-709. PubMed ID: 23995423
[TBL] [Abstract][Full Text] [Related]
16. Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G.
Yao X; Verkman AS
Acta Neuropathol Commun; 2017 Feb; 5(1):15. PubMed ID: 28212662
[TBL] [Abstract][Full Text] [Related]
17. Targeting the complement system in neuromyelitis optica spectrum disorder.
Asavapanumas N; Tradtrantip L; Verkman AS
Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
[TBL] [Abstract][Full Text] [Related]
18. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms.
Zhang H; Bennett JL; Verkman AS
Ann Neurol; 2011 Dec; 70(6):943-54. PubMed ID: 22069219
[TBL] [Abstract][Full Text] [Related]
20. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
